Cargando…

SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence

A successful vaccination would represent the most efficient means to control the pandemic of Coronavirus Disease-19 (COVID-19) that led to millions of deaths worldwide. Novel mRNA-based vaccines confer protective immunity against SARS-CoV-2, but whether immunity is immediately effective and how long...

Descripción completa

Detalles Bibliográficos
Autores principales: La Sala, Lucia, Gandini, Sara, Bruno, Antonino, Allevi, Raffaele, Gallazzi, Matteo, Senesi, Pamela, Palano, Maria Teresa, Meregalli, Paola, Longhi, Ermanno, Sommese, Carmen, Luzi, Livio, Trabucchi, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882867/
https://www.ncbi.nlm.nih.gov/pubmed/35237261
http://dx.doi.org/10.3389/fimmu.2022.798813
_version_ 1784659794147147776
author La Sala, Lucia
Gandini, Sara
Bruno, Antonino
Allevi, Raffaele
Gallazzi, Matteo
Senesi, Pamela
Palano, Maria Teresa
Meregalli, Paola
Longhi, Ermanno
Sommese, Carmen
Luzi, Livio
Trabucchi, Emilio
author_facet La Sala, Lucia
Gandini, Sara
Bruno, Antonino
Allevi, Raffaele
Gallazzi, Matteo
Senesi, Pamela
Palano, Maria Teresa
Meregalli, Paola
Longhi, Ermanno
Sommese, Carmen
Luzi, Livio
Trabucchi, Emilio
author_sort La Sala, Lucia
collection PubMed
description A successful vaccination would represent the most efficient means to control the pandemic of Coronavirus Disease-19 (COVID-19) that led to millions of deaths worldwide. Novel mRNA-based vaccines confer protective immunity against SARS-CoV-2, but whether immunity is immediately effective and how long it will remain in recipients are uncertain. We sought to assess the effectiveness of a two-dose regimen since the boosts are often delayed concerning the recommended intervals. METHODS: A longitudinal cohort of healthcare workers (HCW, N = 46; 30.4% men; 69.6% women; mean age 36.05 ± 2.2 years) with no SARS-CoV-2 infection as documented by negative polymerase chain reaction was immunophenotyped in PBMC once a week for 4 weeks from the prime immunization (Pfizer mRNA BNT162b2) and had received 2 doses, to study the kinetic response. RESULTS: We identified three risk groups to develop SARS-CoV-2 infection IgG(+)-based (late responders, R(-); early responders, R(+); pauci responders, PR). In all receipts, amplification of B cells and NK cells, including IL4-producing B cells and IL4-producing CD8(+) T cells, is early stimulated by the vaccine. After the boost, we observed a growing increase of NK cells but a resistance of T cells, IFNγ-producing CD4(+)T cells, and IFNγ-producing NK cells. Also, hematologic parameters decline until the boost. The positive association of IFNγ-producing NK with IFNγ-producing CD4(+)T cells by the multiple mixed-effect model, adjusted for confounders (p = 0.036) as well as the correlation matrix (r = 0.6, p < 0.01), suggests a relationship between these two subsets of lymphocytes. CONCLUSIONS: These findings introduce several concerns about policy delay in vaccination: based on immunological protection, B cells and the persistent increase of NK cells during 2 doses of the mRNA-based vaccine could provide further immune protection against the virus, while CD8(+) T cells increased slightly only in the R(+) and PR groups.
format Online
Article
Text
id pubmed-8882867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88828672022-03-01 SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence La Sala, Lucia Gandini, Sara Bruno, Antonino Allevi, Raffaele Gallazzi, Matteo Senesi, Pamela Palano, Maria Teresa Meregalli, Paola Longhi, Ermanno Sommese, Carmen Luzi, Livio Trabucchi, Emilio Front Immunol Immunology A successful vaccination would represent the most efficient means to control the pandemic of Coronavirus Disease-19 (COVID-19) that led to millions of deaths worldwide. Novel mRNA-based vaccines confer protective immunity against SARS-CoV-2, but whether immunity is immediately effective and how long it will remain in recipients are uncertain. We sought to assess the effectiveness of a two-dose regimen since the boosts are often delayed concerning the recommended intervals. METHODS: A longitudinal cohort of healthcare workers (HCW, N = 46; 30.4% men; 69.6% women; mean age 36.05 ± 2.2 years) with no SARS-CoV-2 infection as documented by negative polymerase chain reaction was immunophenotyped in PBMC once a week for 4 weeks from the prime immunization (Pfizer mRNA BNT162b2) and had received 2 doses, to study the kinetic response. RESULTS: We identified three risk groups to develop SARS-CoV-2 infection IgG(+)-based (late responders, R(-); early responders, R(+); pauci responders, PR). In all receipts, amplification of B cells and NK cells, including IL4-producing B cells and IL4-producing CD8(+) T cells, is early stimulated by the vaccine. After the boost, we observed a growing increase of NK cells but a resistance of T cells, IFNγ-producing CD4(+)T cells, and IFNγ-producing NK cells. Also, hematologic parameters decline until the boost. The positive association of IFNγ-producing NK with IFNγ-producing CD4(+)T cells by the multiple mixed-effect model, adjusted for confounders (p = 0.036) as well as the correlation matrix (r = 0.6, p < 0.01), suggests a relationship between these two subsets of lymphocytes. CONCLUSIONS: These findings introduce several concerns about policy delay in vaccination: based on immunological protection, B cells and the persistent increase of NK cells during 2 doses of the mRNA-based vaccine could provide further immune protection against the virus, while CD8(+) T cells increased slightly only in the R(+) and PR groups. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882867/ /pubmed/35237261 http://dx.doi.org/10.3389/fimmu.2022.798813 Text en Copyright © 2022 La Sala, Gandini, Bruno, Allevi, Gallazzi, Senesi, Palano, Meregalli, Longhi, Sommese, Luzi and Trabucchi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
La Sala, Lucia
Gandini, Sara
Bruno, Antonino
Allevi, Raffaele
Gallazzi, Matteo
Senesi, Pamela
Palano, Maria Teresa
Meregalli, Paola
Longhi, Ermanno
Sommese, Carmen
Luzi, Livio
Trabucchi, Emilio
SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence
title SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence
title_full SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence
title_fullStr SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence
title_full_unstemmed SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence
title_short SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence
title_sort sars-cov-2 immunization orchestrates the amplification of ifnγ-producing t cell and nk cell persistence
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882867/
https://www.ncbi.nlm.nih.gov/pubmed/35237261
http://dx.doi.org/10.3389/fimmu.2022.798813
work_keys_str_mv AT lasalalucia sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT gandinisara sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT brunoantonino sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT alleviraffaele sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT gallazzimatteo sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT senesipamela sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT palanomariateresa sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT meregallipaola sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT longhiermanno sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT sommesecarmen sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT luzilivio sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence
AT trabucchiemilio sarscov2immunizationorchestratestheamplificationofifngproducingtcellandnkcellpersistence